We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

BioFire Diagnostics

BioFire Diagnostics, a subsidiary of bioMérieux SA, offers easy-to-use clinical molecular diagnostic solutions based ... read more Featured Products: More products

Download Mobile App




Enterovirus D68 Genome Sequenced

By LabMedica International staff writers
Posted on 11 Nov 2014
In recent months, the rare Enterovirus D68 (EV-D68) has spread rapidly across North America and caused severe respiratory illness in young children, with some requiring hospitalization.

Routine laboratory tests cannot identify specific Enterovirus and most hospitals and clinics can only perform tests to determine if a patient has a virus that fits broadly into the Enterovirus/rhinovirus category. More...
As only specialized laboratories can identify the virus, merely 594 cases of EV-D68 infection have been officially confirmed in 43 US states and the District of Columbia.

Scientists at the Washington University School of Medicine (St. Louis, MO, USA) analyzed 14 patient samples testing positive for Enterovirus/rhinovirus. They determined the complete coding sequence of one strain from St. Louis by using high-throughput sequencing of nucleic acid from a clinical sample. To evaluate the sequence diversity in EV-D68 strains circulating in the St. Louis metropolitan area, they also generated partial-genome sequences from eight more EV-D68–positive clinical samples from the immediate area.

Residual material from a subset of nasopharyngeal specimens positive for Enterovirus/rhinovirus that had been tested by the BioFire FilmArray Respiratory Panel (BioFire Diagnostics; Salt Lake City, UT, USA) were selected for high-throughput sequencing. Total nucleic acid was extracted from clinical samples by using NucliSENS easyMAG (bioMérieux; Marcy l'Etoile, France) and used to make dual-indexed sequencing libraries. Enterovirus/rhinovirus sequences were enriched by using a NimbleGen custom sequence capture reagent (Roche/NimbleGen; Madison, WI, USA), which as of February 2014 was selective for all complete Enterovirus and rhinovirus genomes in the GenBank. Sequence data were generated on a HiSeq 2500 (Illumina; San Diego, CA, USA).

Of the 14 patient samples tested, nine were identified as infected with EV-D68 and the remaining five samples were other respiratory viruses. Seven of the nine patients with the EV-D68 strain had severe disease that required admission to the pediatric intensive care unit. The remaining two had moderate symptoms resulting in general hospital admission. Of the five patients with other viruses, three were classified with severe disease. The only two patients discharged home with mild disease did not have the EV-D68 strain.

Gregory A. Storch, MD, a professor of Pediatrics and senior author of the study said, “Having the DNA sequence of this virus enables additional investigative studies. It can be used to create better diagnostic tests. It also may help us understand why this epidemic seems to be producing severe and unusual disease, and why it's spreading more extensively than in the past." The study was published on October 28, 2014, in the journal Emerging Infectious Diseases.

Related Links:

Washington University School of Medicine
BioFire Diagnostics
BioMérieux



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Thyroid Test
Anti-Thyroid EIA Test
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.